Atara biotherapeutics, inc. reports inducement grant under nasdaq listing rule 5635(c)(4)

Thousand oaks, calif.--(business wire)---- $atra #cart--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 3,750 restricted stock units of atara's common stock to one newly hired employee. this award was approved by the compensation committee of atara's board of directors and granted under the atara.
ATRA Ratings Summary
ATRA Quant Ranking